Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.

Young Wha Koh,Bumhee Park,Se Hee Jung,Jae-Ho Han,Seokjin Haam,Hyun Woo Lee

Frontiers in immunology（2023）

引用 0|浏览7

暂无评分

摘要

The EGFR rare mutation form of LUAD shows a higher immune activation state compared to wild-type, L858R, and exon 19 deletion variants, indicating it as a potential target for PD-1/PD-L1 inhibitor therapy.

查看译文

关键词

CD4,CD8,EGFR,PD-1,PD-L1,lung adenocarcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要